Buprenorphine: (Major) Concomitant use of vardenafil and buprenorphine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Buprenorphine; Naloxone: (Major) Concomitant use of vardenafil and buprenorphine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Cabotegravir; Rilpivirine: (Moderate) Concomitant use of vardenafil and rilpivirine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.

Side Effects

Apomorphine: (Moderate) Concomitant use of vardenafil and apomorphine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Consider taking steps to minimize the risk of QT/QTc interval prolongation and TdP, such as avoidance, electrolyte monitoring and repletion, and ECG monitoring, especially in patients with additional risk factors for TdP. Aprepitant, Fosaprepitant: (Major) Do not use vardenafil orally disintegrating tablets with aprepitant, fosaprepitant due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; aprepitant is a moderate CYP3A4 inhibitor when administered as a 3-day oral regimen (125 mg/80 mg/80 mg). Coadministration with another moderate CYP3A4 inhibitor increased the AUC of vardenafil by 4-fold.

The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction

Fosaprepitant is rapidly converted to aprepitant and shares many of the same drug interactions. Monitor for an increase in vardenafil-related adverse effects for several days after administration of a multi-day aprepitant regimen. Aripiprazole: (Moderate) Concomitant use of vardenafil and aripiprazole may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Arsenic Trioxide: (Major) Concomitant use of vardenafil and arsenic trioxide increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Artemether; Lumefantrine: (Major) Concomitant use of vardenafil and lumefantrine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). The degree of QT prolongation associated with rilpivirine is not clinically significant when administered within the recommended dosage range; QT prolongation has been described at 3 times the maximum recommended dose. Ceritinib: (Major) Do not use vardenafil orally disintegrating tablets with ceritinib due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A; ceritinib is a strong CYP3A inhibitor.

Vardenafil Levitra is a prescription medication for erectile dysfunction.
It works by increasing blood flow to the penis.
Vardenafil is marketed under the brand name Levitra.
It typically takes about 25-60 minutes to work.
The effects of vardenafil last up to 4-5 hours.
It should be taken on an empty stomach for faster results.
Common side effects include headache and flushing.
Vardenafil is contraindicated with nitrates.
Do not consume alcohol with vardenafil.
Always follow your doctor's dosage instructions.

Use of vardenafil with other strong CYP3A inhibitors increased the AUC of vardenafil by 10 to 16-fold.

Levitra is available in 10 mg and 20 mg tablets.
The medication is not an aphrodisiac; it enhances ability when sexually stimulated.
Vardenafil is a PDE5 inhibitor class drug.
It can be used by men with diabetes-related erectile issues.
Levitra may cause dizziness; avoid driving after taking.
The medication is approved by the FDA for ED treatment.
Do not use if you have severe liver or kidney problems.
Vardenafil should be stored at room temperature, away from moisture.
It is not suitable for women or children.
Consult your doctor for potential drug interactions.

There may also be an increased potential for QT prolongation.

Product	Dosage	Quantity + Bonus	Price
Levitra Generic	20mg	20 Pills	52.63€ 50.12€
Levitra Generic	60mg	270 + 10 Pills	714.53€ 680.50€
Levitra Original	20mg	12 Pills	81.99€ 78.09€
Levitra Generic	20mg	90 + 8 Pills	180.78€ 172.17€
Levitra Soft Tabs	20mg	120 + 8 Pills	288.52€ 274.78€
Levitra Generic	60mg	180 + 10 Pills	501.43€ 477.55€
Levitra Soft Tabs	20mg	180 + 10 Pills	398.14€ 379.18€
Levitra Generic	60mg	10 Pills	47.42€ 45.16€
Levitra Soft Tabs	20mg	360 + 20 Pills	682.21€ 649.72€
Levitra Generic	60mg	60 + 4 Pills	198.85€ 189.38€
Levitra Professional	20mg	60 + 2 Pills	223.11€ 212.49€
Levitra Generic	20mg	360 + 10 Pills	458.44€ 436.61€
Levitra Generic	10mg	270 + 10 Pills	338.09€ 321.99€

Vardenafil can produce an increase in QTc interval at both therapeutic and supratherapeutic doses. Ceritinib has been reported to cause concentration-dependent QT prolongation. Periodically monitor ECGs and electrolytes during concurrent use of ceritinib and vardenafil oral tablets. Chloramphenicol: (Major) Do not use vardenafil orally disintegrating tablets with chloramphenicol due to increased vardenafil exposure; buy cheapest levitra do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; chloramphenicol is a strong CYP3A4 inhibitor. Chloroquine: (Major) Concomitant use of vardenafil and chloroquine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Chlorpheniramine; Dextromethorphan; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors.

Assessment of study quality

Amisulpride: (Major) Concomitant use of vardenafil and amisulpride increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Avoid concomitant use if possible, especially in patients with additional risk factors for TdP. Consider taking steps to minimize the risk for QT/QTc interval prolongation and TdP, such as electrolyte monitoring and repletion and ECG monitoring, if concomitant use is necessary. Amoxicillin; Clarithromycin; Omeprazole: (Major) Do not use vardenafil orally disintegrating tablets with clarithromycin due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; clarithromycin is a strong CYP3A4 inhibitor.

Phosphodiesterase Type 5 Inhibitors: The Day After

Use of vardenafil with other strong CYP3A4 inhibitors increased the AUC of vardenafil by 10 to16-fold. Use of these drugs together may increase the risk for QT prolongation or vardenafil-related side effects. Clarithromycin has an established risk of QT prolongation and torsade de pointes. Vardenafil may produce an increase in QTc interval at both therapeutic and supratherapeutic doses. Anagrelide: (Major) Concomitant use of vardenafil and anagrelide increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Chlorpheniramine; Dihydrocodeine; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Chlorpheniramine; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Chlorpromazine: (Major) Concomitant use of vardenafil and chlorpromazine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Ciprofloxacin: (Major) Do not use vardenafil orally disintegrating tablets with ciprofloxacin due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A and ciprofloxacin is a moderate CYP3A inhibitor. Cisapride: (Contraindicated) Avoid concomitant use of vardenafil and cisapride due to an increased risk for torsade de pointes (TdP) and QT/QTc prolongation. Citalopram: (Major) Concomitant use of citalopram and vardenafil increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Clarithromycin: (Major) Do not use vardenafil orally disintegrating tablets with clarithromycin due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 24-hour period of vardenafil oral tablets. Class IA Antiarrhythmics: (Major) Vardenafil should be avoided in patients taking Class IA antiarrhythmics (disopyramide, procainamide, and quinidine). Class IA antiarrhythmics are associated with QT prolongation and torsade de pointes (TdP).

Brand Name	Active Ingredient	Medication Type	Typical Dosage	Available Forms
Levitra	Vardenafil	PDE5 Inhibitor	5 mg, 10 mg, 20 mg	Tablets
Staxyn	Vardenafil ODT	PDE5 Inhibitor	10 mg	Orally Disintegrating Tablets
Vidalista	Tadalafil (comparison)	PDE5 Inhibitor	2.5 mg, 5 mg, 10 mg	Tablets

Therapeutic and supratherapeutic doses of vardenafil produce an increase in QTc interval. The effect of vardenafil on the QT interval should be considered when prescribing the drug. Clofazimine: (Moderate) Concomitant use of clofazimine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.

Access through your organization

Bedaquiline: (Major) If possible, avoid the use of vardenafil with bedaquiline due to the risk of QT prolongation. Monitor ECGs if bedaquiline is used in patients receiving other drugs that prolong the QTc interval, such as vardenafil. Discontinue bedaquiline if evidence of serious ventricular arrhythmia or if a QTcF interval greater than 500 ms occurs. Both therapeutic (10 mg) and supratherapeutic (80 mg) doses of vardenafil produce an increase in the QTc interval. Berotralstat: (Major) Do not use vardenafil orally disintegrating tablets with berotralstat due to increased vardenafil exposure; do not exceed a single dose of 5 mg per 24-hour period of vardenafil oral tablets.

Clin. Endocrinol. (Oxf)

Vardenafil is primarily metabolized by CYP3A4/5; berotralstat is a moderate CYP3A4 inhibitor. Bismuth Subcitrate Potassium; Metronidazole; Tetracycline: (Moderate) Concomitant use of metronidazole and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Bismuth Subsalicylate; Metronidazole; Tetracycline: (Moderate) Concomitant use of metronidazole and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Brompheniramine; Dextromethorphan; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Brompheniramine; Phenylephrine: (Minor) The therapeutic effect of phenylephrine injection may be decreased in patients receiving phosphodiesterase inhibitors. Clozapine: (Moderate) Concomitant use of vardenafil and clozapine may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.

How To Get Vardenafil

Asenapine: (Major) Concomitant use levitra professional generic of vardenafil and asenapine increases the risk of QT/QTc prolongation and torsade de pointes (TdP). Atazanavir: (Major) Do not use vardenafil orally disintegrating tablets with atazanavir due to increased vardenafil exposure. Use reduced doses of no more than 2.5 mg every 72 hours of vardenafil oral tablets with increased monitoring for adverse reactions. Vardenafil is primarily metabolized by CYP3A4/5; atazanavir is a strong CYP3A4 inhibitor. Coadministration with other strong CYP3A4 inhibitors increased the AUC of vardenafil by 10 to16-fold.

Who should not take vardenafil?

Atazanavir; Cobicistat: (Major) Do not use vardenafil orally disintegrating tablets with atazanavir due to increased vardenafil exposure. (Major) Do not use vardenafil orally disintegrating tablets with cobicistat due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets. Vardenafil is primarily metabolized by CYP3A4/5; cobicistat is a strong CYP3A4 inhibitor. Coadministration with other strong CYP3A4 inhibitors increased the AUC of vardenafil by 10 to 16-fold. Atomoxetine: (Moderate) Concomitant use of atomoxetine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients. Cobicistat: (Major) Do not use vardenafil orally disintegrating tablets with cobicistat due to increased vardenafil exposure; do not exceed a single dose of 2.5 mg per 72-hour period of vardenafil oral tablets.

Medication	Active Ingredient	Onset of Action	Duration	Typical Dose	Cost
Vardenafil (Levitra)	Vardenafil	25-60 min	Up to 5 hours	10 mg	Moderate
Sildenafil (Viagra)	Sildenafil	30-60 min	4-6 hours	50 mg	Moderate
Tadalafil (Cialis)	Tadalafil	30-60 min	Up to 36 hours	10-20 mg	Higher

Codeine; Phenylephrine; Promethazine: (Moderate) Concomitant use of promethazine and vardenafil may increase the risk of QT/QTc prolongation and torsade de pointes (TdP) in some patients.

Mit Fernheiler Hans-Ulrich BURKHARD

Safety Information